Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

Published:2022-11 Issue:11 Volume:3 Page:100814
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Zhang Yang,Qiu Miao-Zhen,Wang Ju-Feng,Zhang Yan-Qiao,Shen Ao,Yuan Xiang-Lin,Zhang Tao,Wei Xiao-Li,Zhao Hong-Yun,Wang De-Shen,Zhao Qi,Xiong Gao-Zhun,Ji Yan-Ping,Liang Xue-Jun,Xia Gang,Xu Rui-Hua

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference36 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA. Cancer J. Clin.,2021

2. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020;Qiu;Cancer Commun.,2021

3. Cancer incidence and mortality in China, 2015;Zhang;Journal of the National Cancer Center,2021

4. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages;Cho;Ann. Surg Oncol.,2013

5. Evaluation of HER2-based biology in 1, 006 cases of gastric cancer in a Japanese population;Aizawa;Gastric Cancer,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Synthesis at the Interface of Chemistry and Biology;Accounts of Chemical Research;2024-08-28

3. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China;Cancer;2024-08-02

4. Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies;Gastric Cancer;2024-07-04

5. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07